IL33 and Hepatitis: The findings that blockage of IL-33 signaling through an anti-IL-33 antibody reduced NKT-cell activation and ameliorated disease pathogenesis and that pre-treatment with sST2-Fc attenuated liver injury [183] further supported the pro-inflammatory role of IL-33 in ConA-induced hepatitis.